Alpha Cognition Inc.

Recent News

  • Alpha Cognition Appoints Lauren D'Angelo as Chief Commercial Officer to Drive Strategic Growth

    Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce the appointment of Lauren D'Angelo to Chief Commercial Officer. In this role, she will ensure the integrated commercial success of the company. Her initial focus will be to establish the company's commercial strategy to effectively...

    2021-05-04 9:00 AM EDT
  • Alpha Cognition to Host Investor Webcast on May 6th, 2021

    Vancouver, British Columbia--(Newsfile Corp. - April 30, 2021) - Alpha Cognition Inc. (TSXV: ACOG)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it will host a webcast investor presentation on Thursday, May 6th, 2021 at 2:00 PM EDT.During the webcast, Michael McFadden, Chief Executive Officer, will provide a presentation that will cover key areas of Alpha Cognition's business....

    2021-04-30 9:00 AM EDT
  • Alpha Cognition Announces Ms. Colleen Johns as SVP, Product Development Further Strengthening the ALPHA-1062 Drug Commercialization Team

    Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - . Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that Ms. Colleen Johns has been appointed Senior Vice President, Product Development as part of the Company's plan to further develop the operational and commercialization team. Ms. Johns most recently served as the Company's Director...

    2021-04-27 9:00 AM EDT
  • Alpha Cognition Announces Mr. Michael McFadden as Chief Executive Officer and Realignment of Leadership Team for Next Stage of ALPHA-1062 Drug Development

    Vancouver, British Columbia--(Newsfile Corp. - April 12, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that Michael McFadden has been appointed chief executive officer as part of the Company's plan to accelerate growth. Mr. McFadden most recently served as Chief Commercial Officer of MPower Health, a privately held orthopedic healthcare...

    2021-04-12 9:00 AM EDT
  • Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference

    Detroit, Michigan--(Newsfile Corp. - March 23, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company focused on neurological disorders, with near term commercialization potential for its Alpha-1062 Alzheimer's drug announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM ET. The presentation will cover all key aspects of ACI's business including a summary of the de-risked ALPHA-1062 clinical program with its accelerated path to...

    2021-03-23 9:00 AM EDT
  • Alpha Cognition Announces Closing of Qualifying Transaction

    Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - Alpha Cognition Inc. (TSXV: CRYS.P) (formerly Crystal Bridge Enterprises Inc.) (the "Company" or "Alpha Cognition") is pleased to announce the closing of its qualifying transaction (the "Transaction"), as defined in the policies of the TSX Venture Exchange (the "TSXV"), pursuant to which it completed a plan of arrangement (the "Arrangement") with Alpha Cognition Canada Inc. (formerly Alpha Cognition Inc.) ("Alpha Canada"). Pursuant to the Arrangement, the Company acquired 100% of the...

    2021-03-22 9:03 PM EDT
  • Crystal Bridge Provides Transaction Update

    Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) - Crystal Bridge Enterprises Inc. (TSXV: CRYS.P) (the "Company") is pleased to provide an update regarding its Qualifying Transaction (the "Transaction") with Alpha Cognition Inc. ("ACI"), as previously announced on July 14, October 28 and December 4, 2020. The Company is pleased to announce that ACI has obtained an interim order of the Supreme Court of British Columbia providing for, among other things, the holding of ACI's special meeting of shareholders and...

    2021-03-08 8:46 PM EST
  • Crystal Bridge Announces Receipt by Alpha Cognition of Japanese Patent for Alzheimer Drug Alpha-1062 and Announces Private Placement Updates

    Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Crystal Bridge Enterprises Inc. (TSXV: CRYS.P) ("Crystal Bridge", or the "Company") is pleased to announce that Alpha Cognition Inc. ("ACI"), has received confirmation of a patent being granted in Japan for Alpha 1062 drug being developed for use in the treatment of neurodegenerative diseases, including Alzheimer's disease. This patent grant further demonstrates the value of Alpha-1062's patent family globally.The Alzheimer's Association estimates that 4.6 million people in Japan are living...

    2020-12-04 4:27 PM EST